ArticlePloS one2018
BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Defecation status, intestinal microbiota, and habitual diet are associated with the fecal bile acid composition: a cross-sectional study in community-dwelling young participants.European journal of nutrition · 2023Trial
- Article
- Clostridium scindens: history and current outlook for a keystone species in the mammalian gut involved in bile acid and steroid metabolism.FEMS microbiology reviews · 2025Review
- A gut microbiota-independent mechanism shapes the bile acid pool in mice with MASH.JHEP reports : innovation in hepatology · 2024Article
- The Potential of Bile Acids as Biomarkers for Metabolic Disorders.International journal of molecular sciences · 2023Review
- Review
- Evaluation of gut dysbiosis using serum and fecal bile acid profiles.World journal of clinical cases · 2022Review
- Identification of a Bile Acid-Binding Transcription Factor inACS chemical biology · 2022Article
- Metagenomic and bile acid metabolomic analysis of fecal microbiota transplantation for recurrent Clostridiodes difficile and/or inflammatory bowel diseases.Medical research archives · 2022Article
- Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection.Antimicrobial agents and chemotherapy · 2022Article
- Profiling gut microbiota and bile acid metabolism in critically ill children.Scientific reports · 2022Article
- Evaluation of the Risk ofMetabolites · 2022Article
- Bile acid-independent protection against Clostridioides difficile infection.PLoS pathogens · 2021Article
- Descriptive Study of Gut Microbiota in Infected and Colonized Subjects byMicroorganisms · 2021Article
- Application of Microbiome Management in Therapy forPathogens (Basel, Switzerland) · 2021Review
- Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance againstMicroorganisms · 2021Review
- Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology.Nature reviews. Gastroenterology & hepatology · 2021Review
- Treatment issues in recurrentFEMS microbes · 2020Review
- Ridinilazole, a narrow spectrum antibiotic for treatment ofAmerican journal of physiology. Gastrointestinal and liver physiology · 2020Article
- Strain-Dependent Inhibition of Clostridioides difficile by CommensalJournal of bacteriology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClostridium difficile infection (CDI) is a major cause of hospital-acquired diarrhea. Secondary bile acids were shown to confer resistance to colonization by C. difficile. 7α-dehydroxylation is a key step in transformation of primary to secondary bile acids and required genes have been located in a single bile acid-inducible (bai) operon in C. scindens as well as in C. hiranonis, two Clostridium sp. recently reported to protect against C. difficile colonization.
aimTo analyze baiCD gene abundance in C. difficile positive and negative fecal samples. MATERIAL &
methodsA species-specific qPCR for detecting baiCD genes was established. Fecal samples of patients with CDI, asymptomatic toxigenic C. difficile colonization (TCD), non-toxigenic C. difficile colonization (NTCD), of C. difficile negative (NC) patients, and of two patients before and after fecal microbiota transplantation (FMT) for recurrent CDI (rCDI) were tested for the presence of the baiCD genes.
resultsThe prevalence of the baiCD gene cluster was significantly higher in C. difficile negative fecal samples than in samples of patients diagnosed with CDI (72.5% (100/138) vs. 35.9% (23/64; p<0.0001). No differences in baiCD gene cluster prevalence were seen between NC and NTCD or NC and TCD samples. Both rCDI patients were baiCD-negative at baseline, but one of the two patients turned positive after successful FMT from a baiCD-positive donor.
conclusionFecal samples of CDI patients are less frequently baiCD-positive than samples from asymptomatic carriers or C. difficile-negative individuals. Furthermore, we present a case of baiCD positivity observed after successful FMT for rCDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.